Earnings season can be a great time to review one's investments. This is when corporations often take the opportunity to announce business developments which could change their prospects -- and that's exactly what Sanofi (NASDAQ: SNY) recently did. The France-based pharmaceutical giant shared some important news to investors along with its most recent quarterly update, but the market wasn't very receptive.

Sanofi's stock dropped by more than 15% on the heels of its earnings release although it has since recovered some of these losses. Should investors consider investing in Sanofi while its shares are still down?

Continue reading

Source Fool.com